Biosimilar Rituximab in ANCA ‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study
ACR Open Rheumatology · 2026-08 · 8 (8)
DOI: 10.1002/acr2.90119 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift ACR Open Rheumatology, online erschienen am 30.07.2026. Verfasst von Arielle Mendel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Lupus and Vasculitis Clinic, Division of Rheumatology, McGill University, Montréal, Québec, Canada. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Initiative for Outcomes in Rheumatology Care.
Abstract (Originalsprache)
Objective
To evaluate the six‐month effectiveness and safety of rituximab biosimilars compared to the originator in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and outcomes following originator to biosimilar switching.
Methods
We recruited adults with GPA or MPA treated with the rituximab originator or a biosimilar for induction or maintenance, or who switched from originator to biosimilar maintenance (2018–2023). Participants either started the treatment within the preceding six months or were recruited from vasculitis research cohorts. Outcomes included six‐month remission (Birmingham Vasculitis Activity Score [BVAS] version 3 of 0), relapse (BVAS rise after achieving remission requiring treatment), vasculitis damage, and serious adverse events (SAEs).
Results
We studied 207 participants from 9 centers: 132 starting induction (58 originator and 74 biosimilar), 59 starting maintenance (23 originator and 36 biosimilar), and 16 in the “switch” group. Mean age was 56.7 years (SD 17.5), 52% were female, 80% were White, and 70% had GPA. At six months from induction, 51 of 53 (96%) originator and 66 of 73 (90%) biosimilar recipients achieved remission (difference 6%, 95% confidence interval [CI] −4% to 15%), whereas at three months (exploratory) 48 of 51 (94%) and 57 of 72 (79%) recipients, respectively, had achieved remission (difference 15%, 95% CI 2% to 26%). All individuals in the maintenance and “switch” subgroups were in remission at six months. One minor relapse occurred in each of the induction groups and in the originator maintenance group. Change in vasculitis damage and SAEs were not significantly different between groups.
Conclusion
This study found no significant differences in six‐month outcomes between the rituximab originator and biosimilars for induction of GPA and MPA, with no concerning early signals in those initiating maintenance or switching from the originator to a biosimilar.
Autor:innen und Institutionen
- Lupus and Vasculitis Clinic, Division of Rheumatology, McGill University, Montréal, Québec, Canada.
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
- Division of Rheumatology, Department of Medicine, Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
- Division of Rheumatology, University of Alberta, Edmonton, Alberta, Canada.
- Division of Rheumatology, University of British Columbia, Vancouver, British Columbia, Canada.
- Division of Rheumatology, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Arielle Mendel, Lillian Barra, Sasha Bernatsky, Alison H Clifford, Jan Willem Cohen Tervaert, Jean-Paul Makhzoum, Rosalie-Sélène Meunier, Nataliya Milman, Medha Soowamber, Elaine Yacyshyn, Christian Pagnoux
Förderung
- Canadian Initiative for Outcomes in Rheumatology Care
Zitieren
APA
Mendel, A., Barra, L., Behlouli, H., Bernatsky, S., Clifford, A. H., Cohen Tervaert, J. W., Dehghan, N., Fifi-Mah, A., Makhzoum, J. P., Meunier, R. S., Milman, N., Soowamber, M., Yacyshyn, E., Khalidi, N., & Pagnoux, C. (2026). Biosimilar Rituximab in ANCA ‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study. ACR Open Rheumatology, 8(8). https://doi.org/10.1002/acr2.90119
Vancouver
Mendel A, Barra L, Behlouli H, Bernatsky S, Clifford AH, Cohen Tervaert JW, et al. Biosimilar Rituximab in ANCA ‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study. ACR Open Rheumatology. 2026;8(8). doi:10.1002/acr2.90119
BibTeX
@article{Mendel2026,
author = {Mendel, Arielle and Barra, Lillian and Behlouli, Hassan and Bernatsky, Sasha and Clifford, Alison H and Cohen Tervaert, Jan Willem and Dehghan, Natasha and Fifi-Mah, Aurore and Makhzoum, Jean-Paul and Meunier, Rosalie-Sélène and Milman, Nataliya and Soowamber, Medha and Yacyshyn, Elaine and Khalidi, Nader and Pagnoux, Christian},
title = {Biosimilar Rituximab in ANCA ‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {8},
doi = {10.1002/acr2.90119}
}
EUVIMED